Translational Development Acquisition (TDAC) EBIAT (2024 - 2026)
Translational Development Acquisition's EBIAT history spans 3 years, with the latest figure at $1.3 million for Q1 2026.
- On a quarterly basis, EBIAT fell 10.13% to $1.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $6.2 million, a 339.93% increase, with the full-year FY2025 number at $6.4 million, up 9059.65% from a year prior.
- EBIAT came in at $1.3 million for Q1 2026, down from $1.6 million in the prior quarter.
- The five-year high for EBIAT was $1.7 million in Q3 2025, with the low at -$61283.0 in Q3 2024.
- Historically, EBIAT has averaged $953026.5 across 3 years, with a median of $1.4 million in 2025.
- Biggest five-year swings in EBIAT: skyrocketed 96440.77% in 2025 and later fell 10.13% in 2026.
- Year by year, EBIAT stood at -$8044.0 in 2024, then skyrocketed by 19939.5% to $1.6 million in 2025, then fell by 16.49% to $1.3 million in 2026.
- Business Quant data shows EBIAT for TDAC at $1.3 million in Q1 2026, $1.6 million in Q4 2025, and $1.7 million in Q3 2025.